These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 18777740)

  • 1. [Intensive glycemia control of type-2 diabetes mellitus: a real A(D)VANCe or a deep dis(ACCORD)?].
    Lambiel J; Fumeaux T
    Rev Med Suisse; 2008 Aug; 4(166):1734. PubMed ID: 18777740
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intensive glucose control in type 2 diabetes is beneficial].
    Nilsson PM; Attvall S
    Lakartidningen; 2009 Sep 2-8; 106(36):2198. PubMed ID: 19817174
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensive treatment of hyperglycaemia: ACCORD.
    Klein R
    Lancet; 2010 Aug; 376(9739):391-2. PubMed ID: 20594590
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.
    Laffin LJ; Bakris GL
    Diabetes Obes Metab; 2018 Jun; 20(6):1335-1336. PubMed ID: 29424470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control and CAD risk: a heretical thought.
    Orchard TJ
    Diabetes Care; 1999 Jul; 22(7):1220. PubMed ID: 10388997
    [No Abstract]   [Full Text] [Related]  

  • 8. [Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].
    Füchtenbusch M; Hummel M
    MMW Fortschr Med; 2008 Apr; 150(17):42-4. PubMed ID: 18510157
    [No Abstract]   [Full Text] [Related]  

  • 9. Diabetic complications. The importance of glucose control.
    Skyler JS
    Endocrinol Metab Clin North Am; 1996 Jun; 25(2):243-54. PubMed ID: 8799699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Near-norm blood sugar regulation in diabetes. Myocardial infarct rate halved].
    MMW Fortschr Med; 2005 Sep; 147(35-36):4-5. PubMed ID: 16180560
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Riddle MC
    Circulation; 2010 Aug; 122(8):844-6. PubMed ID: 20733112
    [No Abstract]   [Full Text] [Related]  

  • 12. [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"].
    Seufert J
    Dtsch Med Wochenschr; 2008 May; 133(20):1068-70. PubMed ID: 18461525
    [No Abstract]   [Full Text] [Related]  

  • 13. Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
    Monami M; Adalsteinsson JE; Desideri CM; Ragghianti B; Dicembrini I; Mannucci E
    Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):591-8. PubMed ID: 23711419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
    Sjöholm A
    Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperglycemia and cardiovascular risk in NIDDM.
    Uusitupa MI; Niskanen LK
    Diabetes Care; 1995 Jun; 18(6):884-5. PubMed ID: 7555522
    [No Abstract]   [Full Text] [Related]  

  • 16. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.
    Skyler JS; Bergenstal R; Bonow RO; Buse J; Deedwania P; Gale EA; Howard BV; Kirkman MS; Kosiborod M; Reaven P; Sherwin RS; ; ;
    Diabetes Care; 2009 Jan; 32(1):187-92. PubMed ID: 19092168
    [No Abstract]   [Full Text] [Related]  

  • 17. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.
    Skyler JS; Bergenstal R; Bonow RO; Buse J; Deedwania P; Gale EA; Howard BV; Kirkman MS; Kosiborod M; Reaven P; Sherwin RS; ; ;
    Circulation; 2009 Jan; 119(2):351-7. PubMed ID: 19095622
    [No Abstract]   [Full Text] [Related]  

  • 18. Diabetes. Paradoxical effects of tightly controlled blood sugar.
    Taubes G
    Science; 2008 Oct; 322(5900):365-7. PubMed ID: 18927369
    [No Abstract]   [Full Text] [Related]  

  • 19. Glucose control in type 2 diabetes: still worthwhile and worth pursuing.
    Kahn SE
    JAMA; 2009 Apr; 301(15):1590-2. PubMed ID: 19366780
    [No Abstract]   [Full Text] [Related]  

  • 20. Intensive glycemic control and macrovascular events in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Wu H; Xu MJ; Zou DJ; Han QJ; Hu X
    Chin Med J (Engl); 2010 Oct; 123(20):2908-13. PubMed ID: 21034605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.